Next Article in Journal
Exploiting Protein N-Terminus for Site-Specific Bioconjugation
Previous Article in Journal
Selective Targeting of Breast Cancer by Tafuramycin A Using SMA-Nanoassemblies
Previous Article in Special Issue
Development of CDK4/6 Inhibitors: A Five Years Update
Article

Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins

1
Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague, Czech Republic
2
Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
3
Institute of Medical Biochemistry and Laboratory Diagnostics, and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic
4
Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Špitálska 24, 813 72 Bratislava, Slovakia
*
Authors to whom correspondence should be addressed.
Academic Editors: Marialuigia Fantacuzzi and Alessandra Ammazzalorso
Molecules 2021, 26(12), 3528; https://doi.org/10.3390/molecules26123528
Received: 16 March 2021 / Revised: 21 May 2021 / Accepted: 26 May 2021 / Published: 9 June 2021
(This article belongs to the Special Issue Anticancer Inhibitors)
Statins have been widely used for the treatment of hypercholesterolemia due to their ability to inhibit HMG-CoA reductase, the rate-limiting enzyme of de novo cholesterol synthesis, via the so-called mevalonate pathway. However, their inhibitory action also causes depletion of downstream intermediates of the pathway, resulting in the pleiotropic effects of statins, including the beneficial impact in the treatment of cancer. In our study, we compared the effect of all eight existing statins on the expression of genes, the products of which are implicated in cancer inhibition and suggested the molecular mechanisms of their action in epigenetic and posttranslational regulation, and in cell-cycle arrest, death, migration, or invasion of the cancer cells. View Full-Text
Keywords: statins; pancreatic cancer; DNA microarray; pitavastatin; cerivastatin; simvastatin; fluvastatin; atorvastatin; pravastatin; HMG-CoA reductase inhibitors statins; pancreatic cancer; DNA microarray; pitavastatin; cerivastatin; simvastatin; fluvastatin; atorvastatin; pravastatin; HMG-CoA reductase inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Rimpelová, S.; Kolář, M.; Strnad, H.; Ruml, T.; Vítek, L.; Gbelcová, H. Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. Molecules 2021, 26, 3528. https://doi.org/10.3390/molecules26123528

AMA Style

Rimpelová S, Kolář M, Strnad H, Ruml T, Vítek L, Gbelcová H. Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. Molecules. 2021; 26(12):3528. https://doi.org/10.3390/molecules26123528

Chicago/Turabian Style

Rimpelová, Silvie, Michal Kolář, Hynek Strnad, Tomáš Ruml, Libor Vítek, and Helena Gbelcová. 2021. "Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins" Molecules 26, no. 12: 3528. https://doi.org/10.3390/molecules26123528

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop